Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,400 shares of the company’s stock after purchasing an additional 300 shares during the quarter. Catalyst Funds Management Pty Ltd’s holdings in Vaxcyte were worth $1,506,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in PCVX. Janus Henderson Group PLC raised its stake in Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. raised its stake in Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after purchasing an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Vaxcyte by 47.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after purchasing an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Vaxcyte in the 3rd quarter valued at about $41,114,000. Finally, Franklin Resources Inc. raised its stake in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after purchasing an additional 324,560 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

PCVX has been the subject of several analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Finally, Guggenheim reaffirmed a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,250 shares of company stock valued at $4,550,258. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Stock Performance

PCVX opened at $74.37 on Friday. The firm has a 50 day moving average price of $82.24 and a 200 day moving average price of $94.26. The company has a market cap of $9.58 billion, a PE ratio of -16.17 and a beta of 1.02. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.